# Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

> clinical trial · VERIFIED · 2026-06-16

Status: RECRUITING · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Condition: Multiple Sclerosis

- Company: National Institute of Allergy and Infectious Diseases (NIAID)
- Sector: neurology
- Primary source: https://clinicaltrials.gov/study/NCT03109288

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.